Comparative Pharmacology
Head-to-head clinical analysis: TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus TOBRAMYCIN SULFATE PHARMACY BULK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus TOBRAMYCIN SULFATE PHARMACY BULK.
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs TOBRAMYCIN SULFATE (PHARMACY BULK)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death. Bactericidal against Gram-negative aerobes.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
5-7 mg/kg IV q24h (extended-interval) or 1.5-2.5 mg/kg IV q8h (traditional dosing) for serious Gram-negative infections; adjust based on therapeutic drug monitoring.
None Documented
None Documented
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Terminal elimination half-life of 2–3 hours in patients with normal renal function; prolonged to 24–60 hours in anuria/end-stage renal disease. In neonates, half-life may be 4–12 hours depending on gestational age.
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of dose recovered in urine within 24 hours. Biliary/fecal elimination is minimal (<1%).
Category D/X
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic